title: Attacking cancer at its foundation.
authors.affiliation: Grant Biopharma, Jackson, Wyoming, USA. nick.lydon@me.com
authors.forename: Nicholas
authors.initials: N
authors.lastname: Lydon
mesh_terms: D000046:Academic Medical Centers / Q000458:organization & administration*; D001363:Awards and Prizes; D001549:Benzamides; D002986:Clinical Trials as Topic; D015195:Drug Design; D055808:Drug Discovery; D004345:Drug Industry / Q000458:organization & administration*; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D000068877:Imatinib Mesylate; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D010879:Piperazines / Q000138:chemical synthesis / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use; D011743:Pyrimidines / Q000138:chemical synthesis / Q000737:chemistry / Q000145:classification / Q000627:therapeutic use; D014481:United States
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate